News News & Publications IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma October, 2019 Read More... IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares September, 2019 Read More... IGM Biosciences Announces Pricing of Initial Public Offering September, 2019 Read More... IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline July, 2019 Read More... Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis and cell death in vitro and in vivo March, 2019 Read More... IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors January, 2019 Read More... IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer January, 2019 Read More... IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development November, 2018 Read More... Agonistic IgM Antibodies Targeting Immunostimulatory TNFRSF Members GITR and OX40 Enhance Immune Responses beyond that of IgGs November, 2018 Read More... IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors August, 2018 Read More... « Previous 1 2 3 Next »
